Category Specific RSS

jak inhibitors

Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer…

2 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

2 years ago

Out-the-box thinkers are just what the myelofibrosis treatment market needs

The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that…

3 years ago